<table border="0" cellpadding="4" id="inv-148360b6-5d5b-4a93-92f9-f117601aceb6" width="80%" xmlns="urn:hl7-org:v3" xmlns:voc="urn:hl7-org:v3/voc" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption id="inv-fb65afc2-1e84-41bd-9adc-1edbe5b2c843">Table 15. Summary of Drug Interactions With Lamotrigine</caption>
<colgroup>
<col width="34%"></col>
<col width="31.5%"></col>
<col width="34.5%"></col>
</colgroup>
<tbody>
<tr id="id_a54ed927-e34b-4aa0-9a19-1fafbd338f2a">
<td align="center" stylecode="Botrule Lrule Rrule Toprule" valign="middle">Drug</td>
<td align="center" stylecode="Botrule Rrule" valign="middle">Drug Plasma Concentration With Adjunctive Lamotrigine<footnote id="id-3ec366cc-2f5d-4add-8789-04e1bd5b23d5">From adjunctive clinical trials and volunteer studies.</footnote>
</td>
<td align="center" stylecode="Botrule Rrule" valign="middle">Lamotrigine Plasma Concentration With Adjunctive Drugs<footnote id="id-fd325348-007c-4aef-ad8f-bb181f819908">Net effects were estimated by comparing the mean clearance values obtained in adjunctive clinical trials and volunteers studies.</footnote>
</td>
</tr>
<tr id="id_6fe532dc-78c4-4fad-95d9-f85080671ddf">
<td align="left" stylecode="Lrule Rrule" valign="middle">Oral contraceptives (e.g., ethinylestradiol/levonorgestrel)<footnote id="id-807d4bd2-bacc-4782-a1db-84bca2a9023c">The effect of other hormonal contraceptive preparations or hormone replacement therapy on the pharmacokinetics of Lamotrigine has not been systematically evaluated in clinical trials, although the effect may be similar to that seen with the ethinylestradiol/levonorgestrel combinations.</footnote>
</td>
<td align="center" stylecode="Rrule" valign="middle">↔<footnote id="id-65e27f2e-4ea0-46db-97ae-d3a8d0b99b32">Modest decrease in levonorgestrel.</footnote>
</td>
<td align="center" stylecode="Rrule" valign="middle">↓</td>
</tr>
<tr id="id_f55c0749-6add-45da-966a-111ecf55fbc0">
<td align="left" stylecode="Lrule Rrule" valign="middle">Bupropion</td>
<td align="center" stylecode="Rrule" valign="middle">Not assessed</td>
<td align="center" stylecode="Rrule" valign="middle">↔</td>
</tr>
<tr id="id_6c71a1c2-32f9-4003-bbb7-bdcea8e4a539">
<td align="left" stylecode="Lrule Rrule" valign="middle">Carbamazepine (CBZ)</td>
<td align="center" stylecode="Rrule" valign="middle">↔</td>
<td align="center" stylecode="Rrule" valign="middle">↓</td>
</tr>
<tr id="id_d80e4845-e8c7-4491-b3ca-9452596b160f">
<td align="left" stylecode="Lrule Rrule" valign="middle">CBZ epoxide<footnote id="id-35362309-3fde-4740-80c2-d6f329161de8">Not administered, but an active metabolite of carbamazepine.</footnote>
</td>
<td align="center" stylecode="Rrule" valign="middle">?</td>
<td align="center" stylecode="Rrule" valign="middle"></td>
</tr>
<tr id="id_f20b2387-c084-4074-96d2-0e140eacafdc">
<td align="left" stylecode="Lrule Rrule" valign="middle">Felbamate</td>
<td align="center" stylecode="Rrule" valign="middle">Not assessed</td>
<td align="center" stylecode="Rrule" valign="middle">↔</td>
</tr>
<tr id="id_55ca62f3-1c7d-4f21-8b96-5ca0900f999d">
<td align="left" stylecode="Lrule Rrule" valign="middle">Gabapentin</td>
<td align="center" stylecode="Rrule" valign="middle">Not assessed</td>
<td align="center" stylecode="Rrule" valign="middle">↔</td>
</tr>
<tr id="id_c4451a16-1494-40dc-bbc2-ca0644082999">
<td align="left" stylecode="Lrule Rrule" valign="middle">Levetiracetam</td>
<td align="center" stylecode="Rrule" valign="middle">↔</td>
<td align="center" stylecode="Rrule" valign="middle">↔</td>
</tr>
<tr id="id_cf5524be-6b30-4329-8963-8a63b8dcf2ff">
<td align="left" stylecode="Lrule Rrule" valign="middle">Lithium</td>
<td align="center" stylecode="Rrule" valign="middle">↔</td>
<td align="center" stylecode="Rrule" valign="middle">Not assessed</td>
</tr>
<tr id="id_0ae65a17-0893-4f46-a21d-11138ccf0749">
<td align="left" stylecode="Lrule Rrule" valign="middle">Olanzapine</td>
<td align="center" stylecode="Rrule" valign="middle">↔</td>
<td align="center" stylecode="Rrule" valign="middle">↔<footnote id="id-ce24f0f1-c742-44cc-b474-edfffe783946">Slight decrease, not expected to be clinically relevant.</footnote>
</td>
</tr>
<tr id="id_df05c129-a51e-44f0-81a0-c47cf5347ad3">
<td align="left" stylecode="Lrule Rrule" valign="middle">Oxcarbazepine</td>
<td align="center" stylecode="Rrule" valign="middle">↔</td>
<td align="center" stylecode="Rrule" valign="middle">↔</td>
</tr>
<tr id="id_1ffba964-3ab2-435e-8dd3-693bef441915">
<td align="left" stylecode="Lrule Rrule" valign="middle">10-monohydroxy oxcarbazepine metabolite<footnote id="id-9541bca3-6c27-4eb8-a6a5-b5d72d8096a9">Not administered, but an active metabolite of oxcarbazepine.</footnote>
</td>
<td align="center" stylecode="Rrule" valign="middle">↔</td>
<td align="center" stylecode="Rrule" valign="middle"></td>
</tr>
<tr id="id_3ac515bd-2b44-4cc2-9dbb-34e3960b797e">
<td align="left" stylecode="Lrule Rrule" valign="middle">Phenobarbital/primidone</td>
<td align="center" stylecode="Rrule" valign="middle">↔</td>
<td align="center" stylecode="Rrule" valign="middle">↓</td>
</tr>
<tr id="id_729963d8-31f2-49f3-b037-2e748084af98">
<td align="left" stylecode="Lrule Rrule" valign="middle">Phenytoin (PHT)</td>
<td align="center" stylecode="Rrule" valign="middle">↔</td>
<td align="center" stylecode="Rrule" valign="middle">↓</td>
</tr>
<tr id="id_72f3ba42-2760-49ae-812a-2d7c4bcaf90a">
<td align="left" stylecode="Lrule Rrule" valign="middle">Pregabalin</td>
<td align="center" stylecode="Rrule" valign="middle">↔</td>
<td align="center" stylecode="Rrule" valign="middle">↔</td>
</tr>
<tr id="id_37e3b75d-fda5-4f7b-8ca0-5672ef04df33">
<td align="left" stylecode="Lrule Rrule" valign="middle">Rifampin</td>
<td align="center" stylecode="Rrule" valign="middle">Not assessed</td>
<td align="center" stylecode="Rrule" valign="middle">↓</td>
</tr>
<tr id="id_701bcd82-13f2-4ccb-acd3-494684fbdfb2">
<td align="left" stylecode="Lrule Rrule" valign="middle">Topiramate</td>
<td align="center" stylecode="Rrule" valign="middle">↔<footnote id="id-9bb9ddde-3f53-4113-95da-ea72603e17dd">Slight increase not expected to be clinically relevant.</footnote>
</td>
<td align="center" stylecode="Rrule" valign="middle">↔</td>
</tr>
<tr id="id_1bb739bc-f077-4fbe-95f5-f36150d7f539">
<td align="left" stylecode="Lrule Rrule" valign="middle">Valproate</td>
<td align="center" stylecode="Rrule" valign="middle">↓</td>
<td align="center" stylecode="Rrule" valign="middle">↑</td>
</tr>
<tr id="id_ae8504be-2a6a-407c-9212-86b2b499f31e">
<td align="left" stylecode="Lrule Rrule" valign="middle">Valproate + PHT and/or CBZ</td>
<td align="center" stylecode="Rrule" valign="middle">Not assessed</td>
<td align="center" stylecode="Rrule" valign="middle">↔</td>
</tr>
<tr id="id_ebcf9165-bc80-4d23-a5f9-72b08a27565d">
<td align="left" stylecode="Botrule Lrule Rrule" valign="middle">Zonisamide</td>
<td align="center" stylecode="Botrule Rrule" valign="middle">Not assessed</td>
<td align="center" stylecode="Botrule Rrule" valign="middle">↔</td>
</tr>
<tr id="id_136ca919-2bcb-4444-ba79-f53e290c500e">
<td align="left" colspan="3" valign="top">↔ = No significant effect.<br/>? = Conflicting data.</td>
</tr>
</tbody>
</table>